Brief: Codiak Initiates Subject Dosing In A Phase 1 Clinical Trial Of exoIL-12™ For The Treatment Of Cancer
15/09/2020 12:15
Sept 15 (Reuters) - Codiak:
* CODIAK INITIATES SUBJECT DOSING IN A PHASE 1 CLINICAL
TRIAL OF
EXOIL-12™ FOR THE TREATMENT OF CANCER
* CODIAK BIOSCIENCES INC - PRELIMINARY RESULTS FROM HEALTHY
VOLUNTEERS ARE ANTICIPATED BY END OF 2020
* CODIAK BIOSCIENCES INC - SAFETY, BIOMARKER AND PRELIMINARY
EFFICACY RESULTS FROM CTCL PATIENTS ARE ANTICIPATED IN MID-2021
Source text for Eikon: ID:nBw8KJ31ba
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Codiak BioSciences,.
See all newsBrief: Codiak Biosciences Notice From Listing Qualifications Department Of Nasdaq Trading Of Co's Common Stock To Be Suspended At Opening Of Business On April 5
U.S. STOCKS ON THE MOVE-Energy firms, crypto stocks, Walt Disney
U.S. STOCKS ON THE MOVE-Cyclerion, banks, Jounce Therapeutics
U.S. STOCKS ON THE MOVE-Tesla, BrainStorm, Pinterest
Codiak BioSciences down after co files for Chapter 11 bankruptcy